Antibody libraries with maximized antibody developability characteristics

1. A method for producing a human antibody library, comprising:

deriving an antibody heavy chain from the heavy chain of a single human antibody heavy chain variable domain gene or from a single human therapeutic antibody;

providing (a) a first plurality of nucleic acids encoding a population of naturally-occurring antibody heavy chain complementary determining region 1 (CDR1) fragments, (b) a second plurality of nucleic acids encoding a population of naturally-occurring antibody heavy chain complementary determining region 2 (CDR2) fragments, and (c) a third plurality of nucleic acids encoding a population of naturally-occurring heavy chain complementary determining region 3 (CDR3) fragments;

inserting the first plurality of nucleic acids and/or the second plurality and/or the third plurality of nucleic acids into the CDR1 region and/or the CDR2 region and/or the CDR3 region, respectively, of an antibody heavy chain variable domain gene, thereby producing an antibody library;

wherein at least 90% of the population of naturally-occurring antibody heavy chain CDR1 fragments, the population of antibody heavy chain CDR2 fragments, and optionally the population of antibody heavy chain CDR3 fragments is free of members comprising one or more of:

(i) a glycosylation site,

(ii) a deamidation site,

(iii) an isomerization site,

(iv) unpaired cysteine,

(v) net charge greater than 1,

(vi) a tripeptide motif containing at least two aromatic residues,

(vii) a motif that promotes aggregation,

(viii) a poly specificity site;

(ix) a protease sensitive site,

(x) an integrin binding site,

(xi) a lysine glycation site,

(xii) a metal catalyzed fragmentation site,

(xiii) a poly specificity aggregation site; or

(xiv) a streptavidin binding motif.

2. The method of claim 1 , wherein the glycosylation site of (i) comprises the motif NXS, NXT, or NXC, in which X represents any naturally-occurring amino acid residue except for proline;

the deamidation site of (ii) comprises the motif of NG, NS, NT, NN, NA, NH, ND, GNF, GNY, GNT, or GNG;

the isomerization site of (iii) comprises the motif of DT, DH, DS, DG, or DD;

the tripeptide of (vi) is HYF or HWH;

the motif that promotes aggregation of (vii) comprises the motif of FHW;

the polyspecificity site of (viii) comprises the motif GG, GGG, RR, VG, W, WV, WW, WWW, YY, or WXW, in which X represents any amino acid residue

the protease cleavage site of (ix) comprises the motif of DX, in which X is P, G, S, V, Y, F, Q, K, L, or D;

the integrin binding site of (x) comprises RGD, RYD, LDV, or KGD;

the lysine glycation site of (xi) comprises KE, EK, or ED;

the metal catalyzed fragmentation site of (xii) comprises the motif of HS, SH, KT, HXS, or SXH, in which X represents any amino acid residue;

the polyspecificity aggregation site of (xiii) comprises a motif of X1X2X3, wherein each of X1, X2, and X3 independently is selected from the group consisting of F, I, L, V, W and Y; or

the streptavidin binding motif of (xiv) comprises the motif HPQ, EPDW (SEQ ID NO: 117), PWXWL (SEQ ID NO: 118), in which X represents any amino acid residue, GDWVFI (SEQ ID NO: 119), or PWPWLG (SEQ ID NO: 120).

3. The method of claim 1 , wherein the population of human antibody heavy chain CDR3 fragments is derived from B cells.

4. The method of claim 1 , wherein the antibody heavy chain variable region gene is a human heavy chain variable region gene, which optionally is selected from the group consisting of VH1-24, VH2-70, VH3-7, VH4-30-4, VH5-51, VH1-18, VH1-69, VH3-23, VH5-10-1, VH3-9, and VH3-11.

5. The method of claim 4 , wherein the human antibody heavy chain variable region gene is derived from a therapeutic antibody selected from the group consisting of abrilumab, mepolizumab, crenezumab, necitumumab, anifrolumab, and evoculumab.

6. The method of claim 4 , wherein the human antibody heavy chain variable region gene is derived from a therapeutic antibody selected from the group consisting of abituzumab, adalimumab, alemtuzumab, alirocumab, bapineuzumab, benralizumab, brodalumab, canakinumab, certolizumab, clazakizumab, dacetuzumab, daclizumab, daratumumab, eculizumab, efalizumab, elotuzumab, epratuzumab, farletuzumab, fasinumab, ficlatuzumab, fletikumab, fresolimumab, fulranumab, gevokizumab, ibalizumab, lintuzumab, matuzumab, mavrilimumab, mogamulizumab, motavizumab, natalizumab, nivolumab, obinutuzumab, ofatumumab, olokizumab, omalizumab, onartuzumab, otelixizumab, otlertuzumab, palivizumab, panitumumab, panobacumab, pertuzumab, pinatuzumab, polatuzumab, radretumab, ramucirumab, reslizumab, romosozumab, sarilumab, secukinumab, sifalimumab, tabalumab, tigatuzumab, tildrakizumab, tocilizumab, tovetumab, trastuzumab, vedolizumab, veltuzumab, zalutumumab, and zanolimumab.

7. The method of claim 1 , wherein the heavy chain CDR1, CDR2, and CDR3 fragments, the heavy chain variable domain gene, and optionally the light chain CDR1, CDR2, and CDR3 fragments, and the light chain variable domain gene are derived from naturally-occurring antibodies of a mammalian species.

8. The method of claim 7 , wherein the mammalian species is human or camelid.

9. The method of claim 1 , wherein the antibody library is a full-length antibody library, a Fab antibody library, a single-chain antibody library, or a single domain antibody library.

10. The library of claim 1 , wherein the derived antibody heavy chain has up to 5 amino acid substitutions.

11. The library of claim 1 , wherein the library contains at least 10 7 unique CDR3 sequences.

12. The library of claim 1 , wherein the library contains heavy chain CDR3 sequences with greater diversity than the heavy chain CDR1, heavy chain CDR2, light chain CDR 1, light chain CDR2, and light chain CDR3 diversity.